QUICKREADS
World News
Pfizer, Tris Pharma settle for $41.5 million in Texas ADHD drug case
Texas has secured a $41.5 million settlement with Pfizer and Tris Pharma over allegations of drug adulteration related to ADHD medication Quillivant XR, which failed to dissolve properly. The companies deny wrongdoing. The lawsuit stemmed from whistleblower claims about manipulated quality tests, prompting scrutiny of pharmaceutical practices in Medicaid reimbursement and drug safety.
E-Paper

